You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR TIZANIDINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for TIZANIDINE HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00047580 ↗ Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Completed Elan Pharmaceuticals Phase 3 2002-06-01 This study is being conducted to compare the impact of somnolence (sleepiness) on cognition (awareness) as well as the safety and effectiveness of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride tablets) taken while in the fed state (just after a meal) and in the fasted state (before a meal) in patients with moderate to severe spasticity.
NCT00178646 ↗ Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed Allergan Phase 4 2002-01-01 The study seeks to compare the effectiveness of three preparations of BOTOX-A® in treating muscle tightness and spasms in the feet and ankles of people with stroke.
NCT00178646 ↗ Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed The University of Texas Health Science Center, Houston Phase 4 2002-01-01 The study seeks to compare the effectiveness of three preparations of BOTOX-A® in treating muscle tightness and spasms in the feet and ankles of people with stroke.
NCT00228267 ↗ Propofol Injection for Daily Headache Completed University of Alberta Phase 2 2004-09-01 Hypothesis A single subanesthetic dose of propofol will result in improved pain and quality of life for the next 30 days in persons with chronic daily headache (CDH) Specific objectives To measure the effect of a single infusion of propofol at 40 mcg / kg / minute over 60 mins on headache-related quality of life (measured by the Headache Disability Index) and on headache severity (measured by the Headache Index) in subjects with chronic daily headache over 30 days45-47
NCT00287157 ↗ Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI) Completed Teva GTC Phase 1 2006-12-01 Nightly administration of a unique, sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve sleep and next-day functioning in CP (cerebral palsy) patients. It is hypothesized that this improvement in sleep efficiency (i.e.,fewer wake episodes, longer time asleep, etc.) with resulting improvement in quality-of-life (i.e.,improvements in next-day functioning, cognition and movement) may also be seen in a similar patient population, i.e., children with traumatic brain injury (TBI).
NCT00358293 ↗ Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity Completed Teva GTC Phase 1/Phase 2 2006-12-01 Nightly administration of 8 mg of a unique sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve next-day spasticity, about 12 hours following dosing in 20 multiple sclerosis (MS) patients. This improvement was statistically significant when compared to oral tizanidine dosing. The current study is being undertaken to see if increasing the dose to 12 mg once nightly will result in an even greater improvement, with a longer effect, i.e., next day improvement in spasticity both in the morning as well as in the late afternoon.
NCT00464958 ↗ One Year Extension Study To Protocol C2/5/TZ:MS-05 Terminated Teva GTC Phase 1/Phase 2 2008-01-01 Open label, one year extension study to evaluate the clinical efficacy and safety of 12 mg sublingual tizanidine administered once nightly in MS patients who successfully completed Phase I/II protocol C2/5/TZ:MS-05 at the Tel Aviv Sourasky Medical Center, Department of Neurology, Dr. Arnon Karni, PI.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TIZANIDINE HYDROCHLORIDE

Condition Name

Condition Name for TIZANIDINE HYDROCHLORIDE
Intervention Trials
Multiple Sclerosis 3
Spasticity 3
Stroke 2
Cerebral Palsy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TIZANIDINE HYDROCHLORIDE
Intervention Trials
Muscle Spasticity 8
Multiple Sclerosis 4
Cerebral Palsy 3
Neuralgia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TIZANIDINE HYDROCHLORIDE

Trials by Country

Trials by Country for TIZANIDINE HYDROCHLORIDE
Location Trials
United States 31
Canada 4
Korea, Republic of 3
Turkey 3
Israel 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for TIZANIDINE HYDROCHLORIDE
Location Trials
California 4
Texas 3
Pennsylvania 2
Illinois 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TIZANIDINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for TIZANIDINE HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 9
Phase 3 3
Phase 2 3
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TIZANIDINE HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 18
Not yet recruiting 6
Enrolling by invitation 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TIZANIDINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for TIZANIDINE HYDROCHLORIDE
Sponsor Trials
Teva GTC 3
Acorda Therapeutics 2
Second Affiliated Hospital, School of Medicine, Zhejiang University 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TIZANIDINE HYDROCHLORIDE
Sponsor Trials
Other 22
Industry 14
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.